Tycel Phillips, MD, City of Hope, Duarte, CA, highlights the role of targeted therapies in the frontline treatment of mantle cell lymphoma (MCL), and the importance of better incorporating these in clinical practice. Dr Phillips then goes on to discuss clinical trials evaluating various Bruton’s tyrosine kinase (BTK) inhibitors in combination with bendamustine and rituximab (BR). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.